Announcement: Dr. Andrew House named Clark Chair in Nephrology


I am pleased to announce the leader of our Nephrology division, Dr. Andrew House, has been named the inaugural William F. Clark Chair in Nephrology. 

Made possible through an ongoing partnership between Western University, London Health Sciences Foundation (LHSF) and The Kidney Foundation of Canada, the Clark Chair in Nephrology will help fuel the next generation of promising treatments and therapies to help battle kidney disease.

London Health Sciences Centre’s (LHSC) nephrology program is already among the most comprehensive programs in Canada, treating thousands of patients. Through Schulich Medicine’s partnership with LHSC, our faculty and researchers are on the leading edge of breakthroughs to prevent and treat kidney disease.

Backed by a strong partnership, powered by permanently invested funds and led by inaugural Chair Dr. House, the role will power enhanced research, practices, tools and technology, ultimately translating into better care for the one in 10 people affected by chronic kidney disease.

Dr. House, HBSc, MD, MSc, FRCPC is a longtime leader in the Division of Nephrology, having held the position of Chair since 2014. He is the Physician Department Executive for Nephrology at LHSC and is a practicing nephrologist himself. He is also a professor in the Department of Medicine at Schulich Medicine.

He completed his training in Physiology & Pharmacology at Western University before his MD and specialist training at the University of Ottawa, and Masters in Epidemiology & Biostatistics at Western University. As a trained clinical epidemiologist and nephrologist, Dr. House focuses on the design and analysis of clinical trials in acute kidney injury (AKI), chronic kidney disease (CKD), hemodialysis and transplantation.

In 2007, he completed a six-month sabbatical in Vicenza, Italy, where he developed expertise in Critical Care Nephrology and Cardiorenal Syndromes. He collaborates on research into drug metabolism in varying degrees of CKD, and has developed clinical and research expertise in Tuberous Sclerosis Complex.

He has been an invited lecturer at national and international meetings, and is an award-winning teacher of Renal Physiology to medical students.

In addition to Dr. House’s leadership as the Clark Chair, I would also like to note the recent recruitment of a research powerhouse who will help to power ambitious, long-term programs within nephrology.

Made possible through the inaugural endowed Chair funds, Dr. Pavel Roshanov recently joined the School’s faculty as an Assistant Professor of Medicine, Epidemiology & Biostatistics. He has also joined LHSC as a nephrologist.

Dr. Roshanov is a rising star in the nephrology community who has accumulated an impressive array of first author publications, with an h-index of 20 and climbing. His expertise in pharmacotherapy, randomized clinical trials, peri-operative medicine and transplantation are a boon to our existing research bench strength and we are thrilled to have him join our ranks.

With Dr. House as the inaugural Chair and our strong base of existing and newly recruited talent, Schulich Medicine is well-positioned to make an even greater impact than ever before for people diagnosed with kidney disease.

Please join me in celebrating Dr. House, Clark Chair in Nephrology. 


John Yoo, MD, FRCS(C), FACS
Dean, Schulich School of Medicine & Dentistry
Western University